IL17A and Arthritis: If CPP-coupled CS-dIV can be synthesized efficiently, it will be a novel candidate for the therapeutic control of RA-associated joint inflammation, because it can be injected locally and will penetrate inflammatory cells, in which it will function as both an NF-κB and an IL-17 inhibitor, without the risk of systemic effects.